Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21075202 | 1.00 | SCN9A (0.55) | SCN9AROCK2ALDH1A1PDK2SCN5A | |
| SCHEMBL19075763 | 0.89 | ROCK2 (0.49) | SCN9AROCK2ALDH1A1PDK2SCN5A | |
| SCHEMBL19064772 | 0.89 | SCN9A (0.59) | SCN9AALDH1A1SCN5A | |
| SCHEMBL17428307 | 0.89 | SCN9A (0.59) | SCN9AALDH1A1SCN5A | |
| SCHEMBL17423327 | 0.88 | SCN9A (0.52) | SCN9AROCK2ALDH1A1PDK2SCN5A | |
| SCHEMBL17428493 | 0.80 | SCN9A (0.51) | SCN9ASCN5A | |
| SCHEMBL17428497 | 0.79 | SCN9A (0.48) | SCN9AALDH1A1 | |
| SCHEMBL21075107 | 0.79 | ROCK2 (0.46) | SCN9AROCK2ALDH1A1PDK2AVPR2 | |
| SCHEMBL21075496 | 0.79 | SCN9A (0.46) | SCN9AALDH1A1PDK2 | |
| SCHEMBL17423354 | 0.79 | SCN9A (0.54) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2016007534-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SCN9A 2337/4885ROCK2 1043/4885ALDH1A1 1155/4885 |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | SCN9A 2337/4885ROCK2 1043/4885ALDH1A1 1155/4885 |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SCN9A 2337/4885ROCK2 1043/4885ALDH1A1 1155/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | SCN9A 2337/4885ROCK2 1043/4885ALDH1A1 1155/4885 |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SCN9A 2337/4885ROCK2 1043/4885ALDH1A1 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.